LakeShore Biopharma Co Ltd (LSB) USD0.00002

Sell:$1.90Buy:$2.05$0.08 (4.16%)

Prices delayed by at least 15 minutes
Sell:$1.90
Buy:$2.05
Change:$0.08 (4.16%)
Prices delayed by at least 15 minutes
Sell:$1.90
Buy:$2.05
Change:$0.08 (4.16%)
Prices delayed by at least 15 minutes

Company Information

About this company

LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Key people

Yi Zhang
Chairman of the Board
Hui Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
Dave Chenn
Interim Co-Chief Executive Officer, Director
Chunyuan Wu
Chief Financial Officer
Gang Li
Head of Marketing and sales
Yuan Liu
Head of vaccine research
Zenaida Reynoso Mojares
Chief Medical Officer
Chunyang Shao
Director
Bo Tan
Director
Zengjun Xu
Director
Thomas Xue
Director
Adam Zhao
Director
Click to see more

Key facts

  • EPIC
    LSB
  • Location
    China
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    KYG9845F2080
  • Market cap
    $35.30m
  • Employees
    758
  • Shares in issue
    19.08m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.